Research Article

Serum Lactate Dehydrogenase Is a Sensitive Predictor of Systemic Complications of Acute Pancreatitis

Dong-Ni Huang, Hao-Jie Zhong, Ying-Li Cai, Wen-Rui Xie, and Xing-Xiang He

1Department of Gastroenterology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China
2Department of Gastroenterology, Research Center for Engineering Techniques of Microbiota-Targeted Therapies of Guangdong Province, Guangzhou, China
3School of Biology and Biological Engineering, South China University of Technology, Guangzhou, China

Correspondence should be addressed to Wen-Rui Xie; wenruix@gdpu.edu.cn and Xing-Xiang He; hexingxiang@gdpu.edu.cn

Dong-Ni Huang and Hao-Jie Zhong contributed equally to this work.

Received 10 May 2022; Accepted 6 September 2022; Published 25 October 2022

Academic Editor: Jose Celso Ardengh

Copyright © 2022 Dong-Ni Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Acute pancreatitis (AP) is a common and potentially life-threatening inflammatory disease that can cause various complications, including systemic inflammatory response syndrome (SIRS), pleural effusion, ascitic fluid, myocardial infarction, and acute kidney injury (AKI). However, there is still a lack of rapid and effective indicators to assess the disease. The aim of this study was to investigate the associations of high serum lactate dehydrogenase (LDH) levels with AP severity and systemic complications.

Methods. AP patients treated from July 2014 to December 2020 were retrospectively enrolled. They were divided into elevated (n = 93) and normal (n = 143) LDH groups. Their demographic data, clinical data, hospital duration, and hospital expenses were analyzed. Linear and binary logistic regression analyses were used to determine whether elevated LDH is a risk factor for AP severity and complications after adjusting for confounders.

Results. There were significant differences in AP severity scores (Ranson, MODS, BISAP, APACHE II, and CTSI), hospital duration, hospital expenses, and the incidences of complications (SIRS, pleural effusion, ascitic fluid, myocardial infarction, and AKI) between the elevated and normal LDH groups. After adjusting for confounders, elevated LDH was associated with AP severity scores and hospital duration and expenses (based on linear regression analyses) and was a risk factor for the occurrence of AP complications and interventions, that is, diuretic and vasoactive agent use (based on binary logistic regression analyses).

Conclusions. Elevated LDH is associated with high AP severity scores and high incidences of complications (SIRS, pleural effusion, ascitic fluid, myocardial infarction, and AKI).

1. Introduction

Acute pancreatitis (AP) is the most common pancreatic disease in emergency departments [1]. A prospective study reported that the mortality rate of AP is 9.1% [2]. AP can rapidly cause various local and systemic complications, such as acute kidney injury (AKI), respiratory failure, and heart failure [3, 4], which can lead to death [5–7]. Complications represent the most important factor leading to a poor prognosis in patients with AP. Unfortunately, there is a lack of effective, rapid, and simple markers to assess AP complications.

Lactate dehydrogenase (LDH) has been widely used to evaluate AP severity [8]. In addition, several studies have confirmed that serum LDH is increased in heart and chest diseases (e.g., myocardial infarction [9, 10], acute heart failure [11], and pleural effusion [12]). Moreover, a narrative review indicated that elevated LDH in patients with rhabdomyolysis can predict the occurrence of AKI [13]. However, whether LDH is an indicator of complications in patients with AP remains unclear.

Therefore, this study aims to explore the associations of serum LDH with AP severity and systemic complications.
2. Materials and Methods

2.1. Participants. Retrospective data on AP patients treated at the First Affiliated Hospital of Guangdong Pharmaceutical University from July 2014 to December 2020 were included. Exclusion criteria were pregnancy, prior organ transplantation, chronic pancreatitis, and incomplete electronic medical records.

2.2. Data Collection. All data used for the analysis were extracted from the electronic medical records in the hospital database, including age, gender, alcoholism status, smoking status, complications (systemic inflammatory response syndrome [SIRS], pleural effusion, ascitic fluid, myocardial infarction, pancreatic fluid collection, pancreatic necrosis, AKI, acute respiratory failure, and acute heart failure), interventions (diuretic agent use, vasoactive agent use, tracheal intubation, pancreatic surgery, and transfer to intensive care unit), laboratory data (serum amylose, lipase, and LDH, white blood cells [WBC] count, hypocalcemia [serum calcium <2.12 mmol/L], triglycerides, alanine aminotransferase [ALT], aspartate aminotransferase [AST], serum glucose, and C-reactive protein [CRP]), hospital duration, and hospital expenses.

2.3. Definitions. Based on the 2012 revision of the Atlanta classification [4], the diagnosis of AP was based on at least two of the following three features: characteristic abdominal pain, serum amylose or lipase over three times the upper limit of normal, and characteristic findings on abdominal imaging. Elevated serum LDH was defined as >290 U/L [14, 15]. AP severity was assessed according to the Ranson score [16], Multiple Organ Dysfunction Syndrome (MODS) score [17], Bedside Index for Severity in Acute Pancreatitis (BISAP) score [18], Acute Physiology Assessment and Chronic Health Evaluation (APACHE) II score [19], modified Computed Tomography Severity Index (CTSI) [20], and Charlson Comorbidity Index (CCI) [21]. Hypocalcemia was defined as serum calcium <2.12 mmol/L [22]. AKI [23], acute respiratory failure (ARF) [24], and acute heart failure [25] were defined as described in the cited guidelines.

2.4. Statistical Analysis. All data analyses were performed in the SPSS software v22.0 (IBM Corporation, Armonk, NY, USA). Data normality was assessed by the Shapiro–Wilk test. Continuous variables with normal and non-normal distribution were analyzed by t-tests and Mann–Whitney U tests, respectively. Categorical variables were analyzed by chi square tests. Continuous variables are expressed as mean ± standard deviation or median (interquartile range [IQR]), and categorical variables are expressed as frequency (percentage).

Backward stepwise linear regression analyses were used to determine whether elevated LDH (>290 U/L) was a risk factor for AP severity score, hospital duration, and hospital expenses. Backward stepwise binary logistic regression analyses were used to determine whether elevated LDH (>290 U/L) was a risk factor for AP complications and interventions. The analyses were adjusted for potential confounders (gender, age, hypocalcemia, and serum lipase, amylose, glucose, ALT, and AST). Results were considered significant if P < 0.05.

2.5. Ethical Statement. Ethical approval was granted by the institutional review board of the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China (no. 2022-08). The institutional review board waived the requirement for informed consent because of the retrospective nature of the study.

3. Results

3.1. Patient Characteristics. Based on the inclusion and exclusion criteria, 236 patients with AP were enrolled in this
study. They were divided into elevated (n = 93) and normal (n = 143) LDH groups according to serum LDH levels. The demographic and clinical data of the enrolled patients are presented in Table 1.

3.2. AP Severity and Complications. Regarding AP severity, the Ranson, MODS, BISAP, APACHE II, and CTSI scores were significantly higher in the elevated LDH group than those in the normal group (P < 0.001; Table 2). The incidence of SIRS was also significantly higher in the elevated LDH group than that in the normal group (P < 0.001; Table 2).

Regarding the other AP complications, the incidences of pleural effusion (35.66% vs. 54.84%; P < 0.004), ascitic fluid (12.59% vs. 34.41%; P < 0.001), myocardial infarction (0.00% vs. 7.53%; P = 0.003), pancreatic necrosis (8.40% vs. 20.43%; P = 0.032), and AKI (5.59% vs. 20.43%; P < 0.001) were significantly higher in the elevated LDH group than those in the normal group (Table 2).

3.3. Interventions and Outcomes. Regarding interventions, the rate of diuretic agent use was significantly higher in the elevated LDH group than that in the normal group (26.88% vs. 13.29%; P = 0.009; Table 3). Regarding outcomes, hospital duration (9.00; IQR 6.00–14.00 vs. 11.00; IQR 8.00–17.00; P = 0.018) and hospital expenses (20676.39; IQR 14305.52–36604.12 vs. 37414.93; IQR 21378.39–60770.88; P < 0.001) were significantly higher in the elevated LDH group than those in the normal group (Table 3).

3.4. Linear Regression Analyses. The linear regression results showed that after adjusting for potential confounders of the associations of LDH with AP severity scores, the Ranson (β = 1.126, SE = 0.276; P < 0.001), BISAP (β = 0.670, SE = 0.147; P < 0.001), and APACHE II (β = 2.663, SE = 0.715; P < 0.001) scores were significantly higher in the elevated LDH group than those in the normal group (Table 4). Hospital duration (β = 2.231, SE = 0.915; P = 0.016) and hospital expenses (β = 19,288.954, SE = 4975.876; P < 0.001) were also significantly higher in the elevated LDH group than those in the normal group (Table 4).

3.5. Binary Logistic Regression Analyses. The binary logistic regression results showed that after adjusting for potential confounders of the associations of LDH with AP complications and interventions, elevated LDH was a risk factor for pleural effusion (odds ratio [OR] = 1.906; 95% CI [1.057, 3.438]; P = 0.032), ascitic fluid (OR = 2.954; 95% CI [1.173–7.536]; P = 0.019), SIRS (OR = 3.887; 95% CI [2.049–7.376]; P < 0.001), AKI (OR = 4.277; 95% CI [1.656–11.042]; P = 0.003), diuretic agent use (OR = 2.516; 95% CI [1.207–5.247]; P = 0.014), and vasoactive agent use (OR = 7.285; 95% CI [1.420–37.381]; P = 0.017) in patients with AP (Table 5).

4. Discussion

In this study, the AP patients with high LDH levels had severer disease (higher Ranson, MODS, BISAP, APACHE II, and CTSI scores), higher risks of complications (SIRS, pleural effusion, ascitic fluid, myocardial infarction, and AKI), and worse prognosis (higher incidence of diuretic agent use, longer hospital duration, and higher hospital expenses) than those with normal LDH levels. Therefore, assessing LDH at the early stage is likely to be useful for predicting the incidence of complications and then improving prognosis.
Several recent clinical studies have also indicated that serum LDH is a major risk factor for developing complications in multiple diseases. For instance, LDH levels were significantly elevated in patients with rhabdomyolysis-induced AKI [13]. Second, a study of sickle cell anemia showed a significant positive association between LDH and sickle cell anemia-related leg ulcer recurrence [27]. Third, in cardiothoracic surgery patients, the odds of postoperative cardiopulmonary complications increased by nearly 2-fold for each 100 U/L increase in preoperative LDH [28]. Fourth, a study revealed that LDH was considerably higher in patients with malignant ascites than in patients with benign ascites, and it was a risk factor for malignant ascites [29]. Fifth, a retrospective study of 988 patients with metastatic cancer reported that higher LDH was associated with an increased risk of pleural effusion recurrence [30]. Finally, a recent study reported that patients with higher LDH had a higher risk of stage 3 AKI than patients with lower LDH [31]. In line with these previous studies, we found that the incidences of pleural effusion, ascitic fluid, and AKI were 1.906, 2.594, and 4.277 higher in AP patients with elevated LDH than in those with normal LDH.

The relationship between elevated LDH and AP complications can be partly explained by the following factors. First, several AP complications, such as pleural effusion, ascitic fluid, and AKI, are accompanied by inflammatory reactions, which lead to cell damage and necrosis, cause LDH release into the serum, and ultimately raise the level of LDH. Second, research indicates that the primary source of elevated LDH in severe AP is likely to be the kidneys [35] rather than the pancreas [36], indicating that patients with elevated LDH may have renal complications, such as AKI.

In addition, we found that diuretic agent use was higher in the elevated LDH group than that in the normal group, which may be due to there being a higher incidence of AKI in the elevated LDH group. We also found that AP patients with higher LDH have longer hospital duration and higher hospital expenses, which may be related to severer AP and more complications, thus requiring additional medications and monitoring. Consequently, clinicians should carefully monitor serum LDH in AP patients and provide timely preventative interventions if the LDH level is high, in order to improve prognosis.

Our research has several inevitable limitations. First, the lack of blood samples available in this retrospective study limited research on the mechanisms. Second, although we adjusted for many potential confounders in our analyses,
unrecognized residual confounders may still exist, such as the erythrocyte sedimentation rate and the transport time from onset to the hospital. Third, our data came from a single institution, and the sample size was relatively small, so our results require confirmation based on large, multicenter cohort studies.

5. Conclusions

Elevated LDH is associated with both high AP severity scores and high incidences of multiple complications (SIRS, pleural effusion, ascitic fluid, and AKI). Therefore, the levels of LDH in AP patients should be closely monitored after hospital admission so that the complications can be recognized early and treated promptly.

Data Availability

Readers can obtain the datasets of the current study on reasonable request by contacting the author Dong-Ni Huang via email (hdongni@qq.com).

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors would like to express great gratitude to Yi-Ting Zhang for her participation in data collection. This research was supported by the Natural Science Foundation of Guangdong Province (2019A1515010125) and the Department of Education of Guangdong Province (2021KCXTD025).

References

[1] A. Y. Xiao, M. L. Tan, L. M. Wu et al., “Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies,” The Lancet Gastroenterology & Hepatology, vol. 1, no. 1, pp. 45–55, 2016.
[2] S. K. Toh, S. Phillips, and C. D. Johnson, “A prospective audit against national standards of the presentation and management of acute pancreatitis in the South of England,” Gut, vol. 46, no. 2, pp. 239–243, 2000.
[3] R. Maheshwari and R. M. Subramanian, “Severe acute pancreatitis and necrotizing pancreatitis,” Critical Care Clinics, vol. 32, no. 2, pp. 279–290, 2016.
[4] P. A. Banks, T. L. Bollen, C. Dervenis et al., “Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus,” Gut, vol. 62, no. 1, pp. 102–111, 2013.
[5] C. Frey, H. Zhou, D. Harvey, and R. H. White, “Co-morbidity is a strong predictor of early death and multi-organ system failure among patients with acute pancreatitis,” Journal of Gastrointestinal Surgery, vol. 11, no. 6, pp. 733–742, 2007.
[6] R. Mofidi, M. D. Duff, S. J. Wigmore, K. K. Madhavan, O. J. Garden, and R. W. Parks, “Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis,” The British Journal of Surgery, vol. 93, no. 6, pp. 738–744, 2006.
[7] P. K. Garg and V. P. Singh, “Organ failure due to systemic injury in acute pancreatitis,” Gastroenterology, vol. 156, no. 7, pp. 2006–2023, 2019.
[8] F. Tian, H. Li, L. Wang et al., “The diagnostic value of serum C-reactive protein, procalcitonin, interleukin-6 and lactate dehydrogenase in patients with severe acute pancreatitis,” Clinica Chimica Acta, vol. 510, pp. 665–670, 2020.
[9] M. Węggiel, J. Wojtasiak-Bakalarz, K. Malinowski et al., “Mid-regional pro-adrenomedullin and lactate dehydrogenase as predictors of left ventricular remodeling in patients with
myocardial infarction treated with percutaneous coronary intervention,” Polish Archives of Internal Medicine, vol. 132, no. 2, p. 16150, 2022.

[10] A. S. Jaffe, Y. Landi, C. A. Parvin, D. R. Abendschein, E. M. Gelzman, and J. H. Ladenson, ”Comparative sensitivity of cardiac troponin I and lactate dehydrogenase isoenzymes for diagnosing acute myocardial infarction,” Clinical Chemistry, vol. 42, no. 11, pp. 1770–1776, 1996.

[11] E. Poggiali, D. Zaino, P. Immovilli et al., ”Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients,” Clinica Chimica Acta, vol. 509, pp. 135–138, 2020.

[12] X. Y. Shi, F. S. Yi, Z. Wang, X. Qiao, and K. Zhai, ”Prognostic value of a new score using serum alkaline phosphatase and pleural effusion lactate dehydrogenase for patients with malignant pleural effusion,” Thoracic Cancer, vol. 11, no. 2, pp. 320–328, 2020.

[13] H. Heidari Beigvand, K. Heidari, B. Hashemi, and A. Saberinia, ”The value of lactate dehydrogenase in predicting rhabdomyolysis-induced acute renal failure; a narrative review,” Archives of Academic Emergency Medicine, vol. 9, no. 1, article e24, 2021.

[14] B. Rau, M. Cebulla, W. Uhl, M. H. Schoenberg, and H. G. Beger, ”The clinical value of human pancreas-specific protein procarboxypeptidase B as an indicator of necrosis in acute pancreatitis: comparison to CRP and LDH,” Pancreas, vol. 17, no. 2, pp. 134–139, 1998.

[15] O. Komolafe, S. P. Pereira, B. R. Davidson, and K. S. Gurussamy, ”Serum C-reactive protein, procalcitonin, and lactate dehydrogenase for the diagnosis of pancreatic necrosis,” Cochrane Database of Systematic Reviews, vol. 4, no. 4, article CD012645, 2017.

[16] H. Basit, G. J. Ruan, and S. Mukherjee, Ranson Criteria., StatPearls, Treasure Island (FL), 2022.

[17] J. C. Marshall, D. J. Cook, N. V. Christou, G. R. Bernard, C. L. Sprung, and W. J. Sibbald, ”Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome,” Critical Care Medicine, vol. 23, no. 10, pp. 1638–1652, 1995.

[18] B. U. Wu, R. S. Johannes, X. Sun, Y. Tabak, D. L. Conwell, and P. A. Banks, ”The early prediction of mortality in acute pancreatitis: a large population-based study,” Gut, vol. 57, no. 12, pp. 1698–1703, 2008.

[19] W. A. Knau, E. A. Draper, D. P. Wagner, and J. E. Zimmerman, ”APACHE II: a severity of disease classification system,” Critical Care Medicine, vol. 13, no. 10, pp. 818–829, 1985.

[20] K. J. Mortele, W. Wiesner, L. Intriere et al., ”A modified CT severity index for evaluating acute pancreatitis: improved correlation with patient outcome,” American Journal of Roentgenology, vol. 183, no. 5, pp. 1261–1265, 2004.

[21] M. E. Charlson, P. Pompei, K. L. Ales, and C. R. MacKenzie, ”A new method of classifying prognostic comorbidity in longitudinal studies: development and validation,” Journal of Chronic Diseases, vol. 40, no. 5, pp. 373–383, 1987.

[22] J. Pepe, L. Colangelo, F. Biamonte et al., ”Diagnosis and management of hypocalcemia,” Endocrine, vol. 69, no. 3, pp. 485–495, 2020.

[23] R. W. Schrier, W. Wang, B. Poole, and A. Mitra, ”Acute renal failure: definitions, diagnosis, pathogenesis, and therapy,” The Journal of Clinical Investigation, vol. 114, no. 1, pp. 5–14, 2004.

[24] R. Scala and L. Heunks, ”Highlights in acute respiratory failure,” European Respiratory Review, vol. 27, no. 147, article 180008, 2018.

[25] M. Arrigo, M. Jessup, W. Mullens et al., ”Acute heart failure,” Nature Reviews Disease Primers, vol. 6, no. 1, p. 16, 2020.

[26] Z. Yang, L. Dong, Y. Zhang et al., ”Prediction of severe acute pancreatitis using a decision tree model based on the revised Atlanta classification of acute pancreatitis,” PLoS One, vol. 10, no. 11, article e0143486, 2015.

[27] P. Connes, Y. Lamarre, M. D. Hardy-Dessources et al., ”Decreased hematocrit-to-viscosity ratio and increased lactate dehydrogenase level in patients with sickle cell anemia and recurrent leg ulcers,” PLoS One, vol. 8, no. 11, article e79680, 2013.

[28] R. Zhang, T. Kyrius, J. Dippon, E. Boedeker, and G. Friedel, ”Preoperative serum lactate dehydrogenase level as a predictor of major complications following thoracoscopic lobectomy: a propensity-adjusted analysis,” European Journal of Cardio-Thoracic Surgery, vol. 56, no. 2, pp. 294–300, 2019.

[29] Y. Y. Guo, X. L. Peng, N. Zhan, S. Tian, J. Li, and W. G. Dong, ”Development and validation a simple model for identifying malignant ascites,” International Journal of Medical Sciences, vol. 18, no. 9, pp. 1966–1974, 2021.

[30] H. B. Grosu, S. Molina, R. Casal et al., ”Risk factors for pleural effusion recurrence in patients with malignancy,” Respirology, vol. 24, no. 1, pp. 76–82, 2019.

[31] D. Zhang and L. Shi, ”Serum lactate dehydrogenase level is associated with in-hospital mortality in critically ill patients with acute kidney injury,” International Urology and Nephrology, vol. 53, no. 11, pp. 2341–2348, 2021.

[32] N. Zhan, Y. Guo, S. Tian et al., ”Clinical characteristics of COVID-19 complicated with pleural effusion,” BMC Infectious Diseases, vol. 21, no. 1, p. 176, 2021.

[33] W. Hou and A. J. Sanyal, ”Ascites: diagnosis and management,” The Medical Clinics of North America, vol. 93, no. 4, pp. 801–817, 2009, vii.

[34] H. Rabb, M. D. Griffin, D. B. McKay et al., ”Inflammation in AKI: current understanding, key questions, and knowledge gaps,” Journal of the American Society of Nephrology, vol. 27, no. 2, pp. 371–379, 2016.

[35] M. Maekawa, ”Lactate dehydrogenase isoenzymes,” Journal of Chromatography, vol. 429, pp. 373–398, 1988.

[36] C. C. Chen, S. S. Wang, Y. Chao et al., ”C-reactive protein and lactate dehydrogenase isoenzymes in the assessment of the prognosis of acute pancreatitis,” Journal of Gastroenterology and Hepatology, vol. 7, no. 4, pp. 363–366, 1992.